The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease
Neuropsychiatric symptoms (NPS) occur in nearly all patients with Alzheimer's Disease (AD). Most frequently they appear since the mild cognitive impairment (MCI) stage preceding clinical AD, and have a prognostic importance. Unfortunately, these symptoms also worsen the daily functioning of pat...
Main Authors: | Paraskevi Krashia, Elena Spoleti, Marcello D'Amelio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1039725/full |
Similar Items
-
Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease
by: Paraskevi Krashia, et al.
Published: (2019-05-01) -
Expression of Dopamine-Related Genes in Four Human Brain Regions
by: Ansley Grimes Stanfill, et al.
Published: (2020-08-01) -
Cocaine Inhibition of Nicotinic Acetylcholine ReceptorsInfluences Dopamine Release
by: Alexandra eAcevedo-Rodriguez, et al.
Published: (2014-09-01) -
Neural Injury of the Dopaminergic Pathways in Patients with Middle Cerebral Artery Territory Infarct: A Diffusion Tensor Imaging Study
by: Jeong Pyo Seo, et al.
Published: (2023-06-01) -
Structural Connectivity-Based Parcellation of the Dopaminergic Midbrain in Healthy Subjects and Schizophrenic Patients
by: Gianpaolo Antonio Basile, et al.
Published: (2020-12-01)